Services aux conférences Mandl

Résumé: This conference will bring together the research scholars with the aims to disseminate knowledge and facilitate exchange of new ideas amongst them. Obscure issues related to herbal medicines will be focused in the conference "Advances in Phytochemistry and Phytopharmacology" is sponsored by University of Pune, Pune. This three day conference will explore various aspects of Phytocehmistry, herbal standardization, Herbal cosmetics and Phytopharmacology. The eminent personalities from academics and industries will deliver lecture. Pharmacy professionals from academics and industries are expected to attend this three-day scientific convention hosted by our Amrutvahini College of Pharmacy, Sangamner (Maharashtra).

Résumé: Two-day international partnering forum for Bio/Pharma Business Development & Licensing Executives seeking deals in patented and generic (incl. biosimilars), prescription and OTC Drugs, nutraceuticals, and medical devices: development, licensing, marketing, promotion, and distribution. The actual focus is determined by the participating companies’ business interests, displayed as 'Dynamic Partnering Focus' on www.europlx.com.

Résumé: Die Herstellung neuer Substanzen ist in vielen Industriebereichen die Voraussetzung für einen technischen Fortschritt. Oftmals wird ein Glaubenskrieg darüber geführt, welche Methode den Königsweg zur Synthese von Molekülen mit hohem Innovationspotenzial darstellt. Dies ist auch bei den Chemo-und Biokatalytikern nicht anders. In den Vorträgen des Kolloquiums „Kombination von Chemo und Biokatalyse - neue Möglichkeiten für integrierte Prozesse“ wird es darum gehen aufzuzeigen, welche Synergiepotenziale sich durch die Kombination beider Techniken erschließen lassen. Referenten: Prof. Dr. M. Müller, Institut für Pharmazeutische Wissenschaften, Universi-tät Freiburg, Dr. O. May, DSM Pharmaceutical Products, Geleen, NL, Prof. Dr. K. Drauz, Evonik Degussa GmbH, Hanau, Prof. Dr. H. Gröger, Universität Erlangen-Nürnberg, Erlangen, Moderation: Prof. Dr. H. Gröger, Universität Erlangen-Nürnberg, Erlangen

Résumé: The fourth annual BIO-Europe Spring® conference is the premier springtime partnering conference for the biotechnology industry. For its 2010 edition, BIO-Europe Spring moves to Barcelona, Spain on March 8–10, 2010. The conference annually attracts the international “who’s who” from biotech, pharma and finance for three days of high caliber networking. BIO-Europe Spring’s world-class workshops, panels and active exhibition along with thousands of prescheduled one-to-one meetings make this event an unrivalled forum for companies across the biotech value chain to meet and do business. Attend BIO-Europe Spring and experience how you can have more partnering meetings in the three days of the conference than in the rest of the year. Based on attendance at previous events, BIO-Europe Spring 2010 will bring together over 1,500 executives from biotechnology, pharmaceutical and finance companies from around the world, who will engage in over 6,000 partnering meetings. Partnering at BIO-Europe Spring is powered by partneringONE®, the leading conference solution for helping life science delegates meet efficiently and effectively. partneringONE has the unique ability to manage the complex interactions between thousands of executives from many different companies. This sophisticated web-based partnering system enables delegates to screen potential partners, pre-arrange meetings and manage the entire conference partnering process. Delegates can log in and connect with the conference community, anytime, anywhere.

Résumé: In continuation of the successful past scientific meetings in Budapest, Paris, Berlin, Florence, Geneva and Barcelona, the 7th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology will be held in Malta in 2010. This conference has gained an ever increasing impact among the pharmaceutical scientists. With close to 1000 submitted abstracts and 1400 participants a new record was achieved in Barcelona.

Résumé: The program will offer four conferences and workshops listed below. Each conference will feature best practice case studies relevant to clinical operations experts as well as those new to the field. http://www.clinicalops.com/ Conference Programs: Patient Recruitment in Clinical Trials Drug Development Latin America Electronic Data in Clinical Trials eCTD 2010

Résumé: Pharma & Biotech Supply Chain Asia 2010 is the strategic platform where pharmaceutical, biotech and CROs supply chain and logistics practitioners can meet to discuss challenges facing in the Asia context.

Résumé: Biologic Manufacturing World Asia will bring together international and regional biopharmaceutical manufacturers, small biotechs, academic institutions, contract manufacturing service and technology providers to discuss trends, best offshoring, outsourcing and operational strategies for biologic manufacturing, methodologies and technologies to improve productivity, quality, efficiency and profitability.

Résumé: Pharma R&D Partnering World Asia 2010 will bring together international and regional pharmaceutical companies, start-up & spin-off biotechs, research and academic institutions, professional investors, contract research service providers to network and evaluate partnering opportunities in Asia.

Résumé: World Pharma Trials Asia is an event convening pharmas, biotechs, and CROs to explore offshoring & outsourcing opportunities in Asia for cost effective preclinical and clinical drug development, at a time where Asia’s CRO market is growing at a doubling rate yearly, with more and more global pharma and biotechs are offshoring and outsourcing their drug development to Asia.

Résumé: Drug Discovery Technology World Asia 2010 will bring together scientists and discovery technology providers from Asia and globally to discuss and share new tools, innovative methodologies and novel cutting-edge technologies that can be utilized to fast track biomarker research and drug discovery.

Drug Discovery Technology World Asia 2010 is going to be co-located with 4 other conferences, and all 5 conferences will be held alongside a joint exhibition.

Résumé: Pharma & Biotech Supply Chain Asia 2010 brings together pharmaceutical and biotech manufacturers, clinical researchers, distributors and solution providers to address how the industry can collaborate to further strengthen their supply chain in challenging economic conditions to achieve cost optimization, patient safety, product integrity and security in Asia.

Résumé: The expiration of patents on therapeutic biological products raises major technological and policy questions about potential "generic" quivalents – so-called biosimilar or follow-on biologics. While there may be great opportunities for manufacturers and professionals in the biosimilars field, parallel concerns regarding manufacturing, clinical trials, economics, intellectual property, analytical methods, safety and efficacy arise. T he UW Conference on Biosimilars will provide updates and explore potential solutions to these concern.

Résumé: Pharmacy as a profession is currently undergoing a period of unprecedented change, and pharmacy education needs to reflect this. Legislative and other initiatives will have an impact on how and what we teach students, and even more radically, how we assess competencies required to produce the successful pharmacists of the future. This meeting is intended to bring together policymakers and academics to discuss how best the necessary changes can be introduced, and to exchange ideas of best practice.

Résumé: This Congress is organized by BITlifesciences and will present topics concerning the very current advancements in antibody research and product development. Discussion areas will focus on the Emerging Antibody Technologies, Antibody Molecular Targets of Cancers, Targeting Therapeutic Monoclonal Antibody R & D for Major Cancers, Therapeutic MAbs for Various Human Major Diseases, Preclinical /Clinical Studies of Monoclonal Therapeutics, Antibodies for Clinical Diagnostics and Therapy, Antibody Engineering and Production, Bio-Venture on Antibodies.

Résumé: BIT Life Sciences’ Annual World Congress of Vaccine is best known as the largest meeting devoted exclusively to the research on vaccines and associated with technologies for disease prevention and treatment in China. Through a series of impassioned and interesting symposiums, expositions, and poster demonstration, they shared and discussed their valuable and creative ideas, came to the agreement to be the scientific partners and business collaborators, and got the research funding and job opportunities. By right of the successful of WCV-2008, which has attracted 400 excellent presentations and more than 800 participants from both industries and academic areas, we are confident in achieving a more perfect work for our participants to redound upon their trust to the congress.

Résumé: BIT Life Sciences - Annual World Congress of Vaccine is best known as the largest meeting devoted exclusively to the research on vaccines and associated technologies for disease prevention and treatment in China. Through a series of impassioned and interesting symposiums, expositions, and poster demonstration, they shared and discussed their valuable and creative ideas, came to the agreement to be the scientific partners and business collaborators, got the research funding and job opportunities. By right of the successful of WCV-2008, which has attracted 400 excellent presentations and more than 800 participants from both industries and academic areas, we are confident in achieving a more perfect work for our participants to redound upon their trust to the congress.

Résumé: CHI’s successful Alliance Management Congress is growing! Our growth mirrors recent survey results collected from eighty-nine thought leaders in alliance management, diagnostics, medical devices, and licensing. In light of the economy and state of industry, 88% deem alliances as critical and essential to their organization’s alliance activity. During the next 9-12 months, 84% will grow their alliances with new partners including those from academic institutions, diagnostics, medical devices, and international markets. The Collaborations, Deals, and Alliances Congress will house the 7th Annual Alliance Management Congress, the inaugural conference on Collaboration and Deal Making Strategies to Commercialize Molecular Diagnostics, and the 2nd Annual Combination Drug Therapies: Overcoming Challenges in the Development of Fixed Dose and Co-Packaged Combinations. The Collaborations, Deals, and Alliances Congress is for Vice Presidents, Department Heads, Directors, and Managers of Alliance Management, Business Development, Licensing, R&D, Project Management, Clinical Development, and Drug Regulatory Affairs from pharmaceutical, biotech, diagnostics, and medical devices companies. The Collaborations, Deals, and Alliances Congress offers novel case studies, strategies, and techniques from thought leaders who have real-world perspectives to share. There will be case studies of best practice examples, keynotes, industry trends and updates, interactive discussion groups, and panel discussions. The Collaborations, Deals, and Alliances Congress offers multiple conference tracks that provide education for an individual’s area of interest. The Collaborations, Deals, and Alliances Congress also offers joint sessions between the tracks and networking opportunities to provide cross-disciplinary learning.

Résumé: The RPSGB and FIP are pleased to present the return of the Quality International conference for 2010. The conference will explore the process of supplying patients with quality drugs through the supply chain of drug development, industrial manufacturing, distribution and hospital and retail pharmacy dispensing. The key shift in managing quality of medicines in recent years was the introduction of new GMPs for the 21st century and also the initiation of the Quality by Design concept throughout drug development and manufacture. While there have been many conferences on quality concepts, these usually focused on certain aspects of quality in distinct phases of the supply chain such as R&D, manufacturing or distribution. However, it is of paramount importance to understand the impact of quality on the end user - patients. Without such broad understanding the efforts and resources spent on managing quality in isolation in each phase of drug development & distribution can become blurred. Therefore, this conference will be a first time look at the holistic concept of ‘quality of drugs’ to patients!

Résumé: The course is comprised of lectures, delivered by leading experts in each field of ADME, interspersed with interactive workshops centred around practical examples demonstrating how in vitro data generated during drug development can be used to predict:

• Metabolic drug clearance (CL)
• Metabolic drug-drug interactions (DDIs)
• Gut first-pass metabolism
• Oral drug absorption incorporating food effects and the impact of dosage form
• Effect of transporters and enterohepatic recirculation on kinetics
• Drug distribution to different organs
• Population variability in drug concentration-time profiles
• Variation in kinetics in specific populations (paediatrics, ethnic groups, various disease populations)
• Time-course of drug in plasma that fits observed clinical data (achieved using fitting modules within physiologically-based pharmacokinetics (PBPK) models combined with drug specific in vitro information.)

Résumé: The course is comprised of lectures, delivered by leading experts in each field of ADME, interspersed with interactive workshops centred around practical examples demonstrating how in vitro data generated during drug development can be used to predict:

• Metabolic drug clearance (CL)
• Metabolic drug-drug interactions (DDIs)
• Gut first-pass metabolism
• Oral drug absorption incorporating food effects and the impact of dosage form
• Effect of transporters and enterohepatic recirculation on kinetics
• Drug distribution to different organs
• Population variability in drug concentration-time profiles
• Variation in kinetics in specific populations (paediatrics, ethnic groups, various disease populations)
• Time-course of drug in plasma that fits observed clinical data (achieved using fitting modules within physiologically-based pharmacokinetics (PBPK) models combined with drug specific in vitro information.)

Résumé: Medicinal Chemistry as a major tool in delivery of drug candidates plays an important role in drug discovery and development. With ever increasing demand on the MediChem R & D outsourcing to India and China, tremendous number of talented chemists are particularly interested in grasping the current themes in modern medicinal chemistry.

Résumé: The 46th edition of the prestigious International Conference on Medicinal Chemistry (RICT 46) will take place from 30 June till 2nd of July in Reims in the Faculty of Pharmacy. It is in direct continuity with the Region Centre actions in the field of Health, which will soon be strengthened by the creation of a “Pôle Pharma”. The scientific program, approved by the industrial and academic members of the scientific committee, is focused on drug discovery and selection. Various major and fascinating topics, going from biological, bio-physical and computing tools, through screening and organic synthesis to the discovery of new treatments, are proposed.

Résumé: How can pharmacists best support patients in their healthcare decisions? How can the profession be supported in dealing with workplace and commercial pressures while maintaining commitment to high quality patient care? These are just some of the issues that the Royal Pharmaceutical Society will address at its new conference in 2010.

This brand new event will have a practice and professional focus and will explore patient and professional decision making - how pharmacists, as professionals, can lead the way in maximising the optimal use of medicines, maintaining the best interests of patients and in making the best possible decision during times of workplace stress. This is an opportunity for pharmacists to develop leadership skills and to network and see how such networking has been developed at local levels across the countries.

Résumé: Drug Analysis 2010 will be held in Antwerp, in the University Campus of Antwerp. This international symposium will be a joint meeting of two distinguished series: the 9th International Symposium on Drug Analysis and the 22nd International Symposium on Pharmaceutical and Biomedical Analysis. It follows a series of successful symposia on Drug Analysis organized by the Belgian Society of Pharmaceutical Sciences (BSPS) since 1983. This symposium will cover all aspects of pharmaceutical and biomedical analysis, including emerging domains, such as ‘omics’, process analytical technology and green analysis.

Résumé: The conference will focus on advanced characterisation techniques for drug delivery systems and gather scientists in formulation development and in pharmaceutical R&D from all over the world.

Résumé: In the wake of ICC-2009, on behalf of the organizing committee of ICC2010, I am honored to announce that BIT's 2nd International Congress of Cardiology (ICC) will be held during December 7-9, 2010, Shanghai, China. Which will have 10 chapters and about 150 sessions. On December 5-7, 2009, the 1st International Congress of Cardiology (ICC-2009) was held successfully in Shanghai, China. Nearly 200 experts take part in the opening ceremony. Dr. Xiaodan Mei, the Executive Chairman of this event delivered the opening remarks to welcome all our participants. And four keynote speakers of Dr. C. Richard Conti, professor from University of Florida, Dr. Daniel Loisance, professor from Henri Mondor Hospital, Dr. Dan J. Fintel, professor from Feinberg School of Medicine and Dr. John Shryock, senior director from Gilead Sciences shared their research and made splendid speeches. During the conference, nearly 150 speakers make their contribution to it.

Résumé: The IDDST congress is initiated by BIT Life Sciences in 2003, with 7 years¡¯ contribution in the field of drug discovery and development, it has became a leading international event for the professionals to pinpoint and identify opportunities and market needs, explore Asian demand and get updated on latest breakthroughs in drug R&D.

Résumé: ISOPT Asia will follow the footsteps of ISOPT 8th in Rome allowing participants to have a glimpse to the near future with critical look at the current best practices available to our patients today. ISOPT program is geared to provide a continuum, spreading from basic development of therapeutic concepts to their utilization as drugs and technologies in clinical reality. Keeping to our tradition we will be creating a comfortable atmosphere for discussions and updates. The current meeting venue, the Macau Hilton, offers magnificent options for any sort of formal and informal meetings that will complement ISOPT main hall activities.